Literature DB >> 12410490

The safety of voriconazole.

Brian A Potoski, Jack Brown.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12410490     DOI： 10.1086/343746

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  18 in total

1.  Altered pharmacokinetics of voriconazole in a patient with liver cirrhosis.

Authors:  Stefan Weiler; Heinz Zoller; Ivo Graziadei; Wolfgang Vogel; Rosa Bellmann-Weiler; Michael Joannidis; Romuald Bellmann
Journal:  Antimicrob Agents Chemother       Date:  2007-07-02       Impact factor: 5.191

Review 2.  Antifungal therapeutic drug monitoring: established and emerging indications.

Authors:  David Andes; Andres Pascual; Oscar Marchetti
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

3.  Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole.

Authors:  Brad Moriyama; Sameer Kadri; Stacey A Henning; Robert L Danner; Thomas J Walsh; Scott R Penzak
Journal:  Curr Fungal Infect Rep       Date:  2015-04-16

4.  Population pharmacokinetic evaluation with external validation and Bayesian estimator of voriconazole in liver transplant recipients.

Authors:  Kelong Han; Robert Bies; Heather Johnson; Blair Capitano; Raman Venkataramanan
Journal:  Clin Pharmacokinet       Date:  2011-03       Impact factor: 6.447

5.  Voriconazole therapeutic drug monitoring.

Authors:  J Smith; N Safdar; V Knasinski; W Simmons; S M Bhavnani; P G Ambrose; D Andes
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

6.  Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Spain.

Authors:  Alfonso Domínguez-Gil; Isabel Martín; Mercedes García Vargas; Almudena Del Castillo; Silvia Díaz; Cristina Sánchez
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

7.  Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome.

Authors:  Gloria N Mattiuzzi; Jorge Cortes; Gladys Alvarado; Srdan Verstovsek; Charles Koller; Sherry Pierce; Deborah Blamble; Stefan Faderl; Lianchun Xiao; Mike Hernandez; Hagop Kantarjian
Journal:  Support Care Cancer       Date:  2009-12-03       Impact factor: 3.603

8.  Hepatic safety of voriconazole after allogeneic hematopoietic stem cell transplantation.

Authors:  I Amigues; N Cohen; D Chung; S K Seo; C Plescia; A Jakubowski; J Barker; Genovefa A Papanicolaou
Journal:  Biol Blood Marrow Transplant       Date:  2009-10-09       Impact factor: 5.742

9.  Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects.

Authors:  Emma Andrews; Bharat D Damle; Annie Fang; Grover Foster; Penelope Crownover; Robert LaBadie; Paul Glue
Journal:  Br J Clin Pharmacol       Date:  2008-02-21       Impact factor: 4.335

Review 10.  [Keratomycosis: diagnosis and therapy].

Authors:  W Behrens-Baumann
Journal:  Ophthalmologe       Date:  2009-05       Impact factor: 1.059
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.